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Abstract
Background The few available studies directly compar-
ing aseptic and septic joint revision surgery report con-
ﬂicting results. We investigated whether two-stage revision
of septic hip prosthesis with a preformed antibiotic-loaded
spacer and an uncemented prosthesis provides hip function
and quality of life similar to those provided by aseptic
revision surgery in the medium term, as well as the asso-
ciated direct hospital costs.
Materials and methods We prospectively evaluated the
hip function (Harris hip score) and quality of life
(WOMAC and SF-12 scores) of 80 patients who underwent
one-stage revision for aseptic loosening (Group A, 40
patients) or two-stage revision for septic total hip pros-
theses (Group S, 40 patients). Patients were matched for
gender, age, and bone loss. A preformed antibiotic-loaded
cement spacer was used for two-stage revision, and unce-
mented modular prostheses were implanted at revision in
both groups. The minimum follow-up was 2 years (average
4 years; range 2–6 years).
Results We found no difference in infection recurrence or
aseptic loosening rate in the two groups. Average Harris hip
score increased similarly in both groups: from 19.1 to 74.0
in Group A versus 15.0–71.2 in Group S. Patient-reported
quality-of-life questionnaires (SF-12 and WOMAC) at last
follow-up were similar postoperatively, but the complica-
tion rate for Group S was twice that of Group A (20.8 versus
10%). Mean overall hospital-related costs of two-stage
procedures were 2.2 times greater than those for aseptic
revisions.
Conclusions Two-stage revision for infected hip pros-
theses, using a preformed antibiotic-loaded cement spacer
and uncemented revision prosthesis, offers a success rate
comparable to noninfected revisions in the medium term
but is associated with a higher complication rate and costs.
Keywords Hip  Infection  Revision  Two-stage 
Outcome
Introduction
Joint prosthesis infection has been recently reported as the
third most common reason for revision in the United States
[5] after instability/dislocation and aseptic mechanical
loosening. Two-stage revision is the most widely accepted
and performed intervention for septic hip prostheses, with
an infection eradication rate exceeding 90% in most studies
[3, 9, 10, 13, 17, 20, 23, 27, 28, 31, 35, 36]. Despite its
ability to control infection, the functional outcomes of
revision surgery of septic cases are reportedly lower than
those from aseptic revision, as described by Barrack et al.
[4] and Wang et al. [33]. However, no previous study has
directly compared two-stage revision of septic hip pros-
thesis with aseptic revision.
We therefore investigated whether patients undergoing
two-stage revision for septic hip prosthesis or aseptic hip
revision had similar (1) similar functional scores, (2) self-
reported qualities of life, (3) postoperative infection and
complication rates, and (4) radiographic signs of prosthetic
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direct hospital costs connected with the two procedures.
Materials and methods
We prospectively followed 40 patients who underwent one-
stage revision for aseptic loosening (Group A) and 40 who
underwent two-stage revision for septic total hip prosthesis
(Group S) from 2001 to 2006. Sample size determination
was carried out on the basis of the mean values and stan-
dard deviations that have been reported for the functional
scores (WOMAC score) associated with septic and aseptic
revision of total knee arthroplasty [24]. A sample size of
approximately 35 patients per group was needed to achieve
90% power to detect differences of 10% between groups
assuming a pooled standard deviation of 20% using the
unpaired Student’s t test. Patients were matched for gender,
age, and bone loss (Table 1). There was no difference
(P = 0.31) between the mean ± SD preoperative Harris
hip scores of Groups A (19.1 ± 18.5; range 12–62) and S
(15.0 ± 17.7; range 12–50). Six patients in Group A and 9
in Group S had had one previous revision surgery. Three
patients were lost to follow-up: two in Group A and one in
Group S; therefore, a total of 77 hips were available for
follow-up at a minimum of 2 years (mean, 4 years; range
2–6 years). The study was approved by the local Institu-
tional Review Board and Ethics Committee. All of the
patients provided informed consent for enrollment in the
study, which conformed to the Declaration of Helsinki.
We classiﬁed patients according to the Cierny–Mader
classiﬁcation [7]. In this classiﬁcation, hosts affected by
bone infection are divided into three classes: Type A hosts
have a normal, uncompromised, immune system; Type B
are locally and/or systemically immunocompromised hosts;
and Type C are patients that are not considered surgical
candidates (surgical treatment is more compromising to the
patient than the disability caused by the disease itself).
There were more Type B hosts in Group S than in Group
A: 20 of 40 in Group S and 8 of 40 patients in Group A.
Aseptic loosening was conﬁrmed in all cases by
preoperative C-reactive protein (CRP) and erythrocyte
sedimentation rate (ESR) values below or equal to,
respectively, 10 mg/l and 20 mm/h, and negative intraop-
erative cultures [15]. The reasons for aseptic revision were
mechanical loosening of components resulting from poly-
ethylene wear and osteolysis (35 hips), metallosis (two
cases), and recurrent dislocation (3 hips). In Group A, the
average time from the initial THA to one-stage revision
was 71 ± 28 months (range 15–161 months). The initial
diagnosis had been primary osteoarthritis in 22 patients, hip
dysplasia in 12, femoral head necrosis in 4, and femoral
neck fracture in 2 patients.
Diagnosis of infection in the patients included in Group
S was based on the presence of one or more of the fol-
lowing conditions: (1) a draining ﬁstula; (2) positive
intraoperative cultures in at least two samples out of ﬁve;
(3) positive histologic ﬁndings and preoperative elevated
CRP values (greater than 15 mg/l). Samples for frozen-
section analysis and permanent histological analysis were
obtained from the pseudocapsule, the membrane around the
prosthesis, or tissue that was suspected of being infected.
Each of two samples from each patient were divided into
two parts, one for frozen-section analysis and one for
Table 1 Patients details Preoperative data Group A Group S P value
Number of patients 40 40
Male/female 26/14 22/18
Average age (range) 64.4 ± 6.4 65.3 ± 8.6 0.5
Body weight (kg) 68.3 ± 7.5 64.9 ± 7.3 0.06
Body height (cm) 163.5 ± 9.4 160.1 ± 8.8 0.08
Type B hosts 8 20 0.01
Harris hip score 19.1 ± 18.5 (range 12–62) 15.0 ± 17.7 (range 12–50) 0.3
Previous revisions 0.15 ± 0.36 0.22 ± 0.42 0.4
Follow-up (months) 50.5 ± 11.8 52.1 ± 11.7 0.5
Bone loss (Paprosky)
Acetabulum type 1 5 4
Acetabulum type 2 22 20
Acetabulum type 3 13 16
Femur type 1 2 1
Femur type 2 8 6
Femur type 3 18 22
Femur type 4 12 11
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123permanent parafﬁn-embedded section analysis. The sam-
ples that were used for frozen-section analysis were snap-
frozen in carbon dioxide; 4 lm sections were then cut and
stained with hematoxylin and eosin. The samples used for
histological analysis of parafﬁn-embedded sections were
ﬁxed in formalin and embedded in parafﬁn prior to staining
with hematoxylin and eosin. The most cellular areas in the
tissue sample were chosen for evaluation, and the number
of neutrophils (in the frozen and parafﬁn-embedded sec-
tions), lymphocytes, and plasma cells (in the parafﬁn-
embedded sections) per high-power ﬁeld (4009) in at least
ten separate microscopic ﬁelds were counted. The histo-
logical Feldman criterion, deﬁned as the presence of at
least ﬁve neutrophils per high-power ﬁeld (4009)i na t
least ﬁve separate microscopic ﬁelds, was used [2, 14, 19].
The average time from the initial THA to the revision in
Group S was 29 ± 28 months (range 8–61 months). Sev-
enty percent of the isolated Staphylococci, the most fre-
quently cultured pathogen in patients from Group S, were
oxacillin resistant (Table 2). Bacteriologic examinations of
four hips found no growth, in which case the diagnosis of
infection was made by clinical ﬁndings and histologic
examination.
All patients were operated on through a lateral approach
with the patient lying in the supine position, and all
underwent revision of both hip prosthetic components.
In Group S, the infected hip prosthesis was removed and
a preformed antibiotic-loaded spacer (InterSpace
 Hip;
Tecres SpA, Verona, Italy; Exactech Inc., Gainesville, FL,
USA) was implanted. The InterSpace
 Hip is an off-the-
shelf polymethylmethacrylate antibiotic-loaded preformed
hip spacer. The inner part of the spacer features a stainless
still rod that increases mechanical resistance. The cement is
preloaded by the manufacturer with gentamicin at a con-
centration of 1.9%. The InterSpace
 Hip is available with
three different head sizes and with two stem sizes, short
(260 mm) and long (360 mm), that may be chosen intra-
operatively (Fig. 1). The spacer was ﬁxed only in the
proximal part (Fig. 2), to prevent implant rotation, with one
pack of antibiotic-loaded cement (Cemex Genta; Tecres
Spa) containing gentamicin 1.9% and vancomycin 5%. The
vancomycin powder was thoroughly mixed with the
cement powder into a ﬁne consistency before the addition
of liquid monomer. Cement mixing was performed without
vacuum. No bone grafts were used at the time of spacer
implantation.
After surgery, systemic antibiotics were administered
for 4–6 weeks on the basis of antibiogram, when available.
The most commonly used antibiotic regime was a combi-
nation of two parenteral antibiotics (a glycopeptide and a
carbapenemic) for 2 weeks followed by a combination of
two oral antibiotics (rifampicin and a ﬂuoroquinolone) for
the remaining 2–4 weeks. Patients were allowed to sit in a
chair on the second day after operation and partial
weightbearing (10–15 kg on the operated leg) with two
crutches from the third postoperative day until revision
surgery. Isometric and isotonic exercises were usually
Table 2 Organisms cultured in the septic group of 40 patients
Isolated microorganism Number
Staphylococcus epidermidis 16
Staphylococcus aureus 15
Oxacillin-resistant Staphylococci 22
Streptococcus 4
Pseudomonas aeruginosa 4
Enterococcus 4
Peptostreptococcus 2
Propionibacterium 2
Serratia liquefaciens 1
Corynebacterium 1
Fig. 1 The preformed antibiotic-loaded spacer used in the study for
two-stage hip revision (InterSpace
 Hip; Tecres SpA, Verona, Italy;
Exactech Inc., Gainesville, FL, USA). The spacer comes in three
different head sizes and two stem sizes: short (260 mm, shown in
ﬁgure) and long (360 mm). The size may be chosen intraoperatively
by the surgeon on the basis of reusable trials
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123continued in a rehabilitation center within our hospital until
the 20th postoperative day.
Follow-up included blood testing (cell count with dif-
ferential, CRP, ESR, liver and renal function) every
2 weeks and clinical examination with a plain radiograph
of the hip and femur 45 days after surgery. Patients with
successful eradication of their infection, as evidenced
clinically and by a complete blood count with differential
and CRP within the normal ranges, underwent the second
stage of their reconstruction. If clinical suspicion of per-
sistent infection remained, joint aspiration before reim-
plantation was performed for cultures and white blood cell
count. In all cases, intraoperative cultures were obtained at
the time of the second-stage procedure. At revision, the hip
was exposed through the same lateral incision and the
spacers were removed. Reimplantation was performed
9–16 weeks after the spacer implantation.
In both groups (A and S), revision surgery was per-
formed with modular titanium cementless femoral com-
ponents (PROFEMUR
 Hip System; Wright Medical
Group Inc., Arlington, TN, USA, or S-ROM; DePuy
Orthopaedics Inc., Warsaw, IN, USA). Unconstrained
cementless acetabular components were used in all cases.
Eight hips in Group A and 6 in Group S had cancellous
bone grafts for bone defects.
Touchdown weightbearing was allowed for 6 weeks,
followed by 50% weightbearing for 6 weeks. Full
weightbearing and abductor strengthening were permitted
12 weeks after surgery. After each procedure, closed suc-
tion drainage was inserted and removed after 48 h. All
patients received 0.4 mL enoxaparin per day for 30 days
after surgery to prevent thromboembolic complications and
200 mg celecoxib twice a day for 10–14 days after revision
surgery to prevent heterotopic ossiﬁcations [30].
Clinical and radiographic assessments were performed
by an independent observer (DR) who was not associated
with the treatment preoperatively, at the time of spacer
removal, and at the latest follow-up after reimplantation.
Bone defect classiﬁcation, according to Paprosky [8], was
performed intraoperatively by the surgeon at the time of
spacer implantation and at revision. Hip function was
recorded using the Harris hip score [13]. Clinical signs of
infection (redness, swelling, pain, ﬁstulae) and other
complications (deep venous thrombosis and/or pulmonary
embolism, postoperative hemorrhage, dislocation, and
nerve palsy) were also recorded at follow-up. Laboratory
tests at each visit consisted of a complete blood count with
differential, ESR, CRP, urea and creatinine, and a creati-
nine clearance test.
Patient-reported quality-of-life (QOL) outcomes were
assessed pre- and postoperatively through an Italian
translation of the WOMAC questionnaire evaluated at its
subscales [18]. Each raw score was transformed into a
0–100 scale, with 0 being the worst QOL and 100 the best
QOL. An Italian translation of the SF-12 questionnaire
[1, 34] was also administered to all the patients, but only
postoperatively.
Plain radiographs included anteroposterior and lateral
views of the hip. Radiographic examination was performed
preoperatively, at spacer removal, at reimplantation, and
then at 3, 6, and 12 months postoperatively, followed by
yearly intervals thereafter.
Primary outcomes included (1) Harris hip score, (2)
patient-reported QOL evaluated through the SF-12 and
WOMAC questionnaires, (3) postoperative infection and
complication rates, and (4) radiographic signs of prosthetic
loosening and rerevision rate. Secondary outcome was an
estimate of the direct hospital costs of the two procedures.
To this end, we performed a retrospective cost identiﬁca-
tion study on the two cohorts of patients, Groups A and S.
Data on resource use included costs of operating room
equipment and implants (including bone grafts or bone
substitutes), operative staff and time, hospital stay in the
surgical and rehabilitation departments, blood, pharmacy
and administrative costs per patient, as extracted from the
hospital administrative decision support database.
The differences in the Harris hip score, WOMAC and
SF-12 scores, leg length discrepancy, and hospital costs
between Groups A and S were determined using the
unpaired Student’s t test. The complication rate difference
between groups, considered a categorical variable, was
analyzed by the two-tailed Fisher’s exact test. The software
used for statistical analysis was GraphPad InStat from
GraphPad Software, Inc. (San Diego, CA, USA).
Results
At a mean follow-up of 4 years postoperatively, the Harris
hip scores increased to, respectively, 74.0 ± 13.4 (range
Fig. 2 An intraoperative photograph shows that the preformed
cement spacer is only proximally ﬁxed with antibiotic-loaded cement
to prevent rotational instability and unwanted sinking of the implant
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12361–88) and 71.2 ± 14.1 (range 55–86) (P = 0.37) in
Groups A and S. Average leg length discrepancy was
1.3 ± 0.9 cm in Group A and 1.5 ± 1.0 cm in Group S
(P = 0.35).
The physical functional domain of the WOMAC score
was better for Group S than for Group A both pre- and
postoperatively. On average, Group A patients reported
more pain preoperatively than patients in Group S; this
difference was no longer present after revision (Table 3).
The mean SF-12 score at last follow-up was similar for
the two groups for the physical (P = 0.09) and the mental
well-being (P = 0.25) components (Group S: mental
component score: 43.1 ± 13.8, physical component score:
35.6 ± 12.4; Group A: 48.7 ± 14.9 and 32.2 ± 13.4,
respectively).
The postoperative infection rates were similar, with one
deep infection in each group that required further surgery
within 2 years of revision. There were 5 intraoperative
complications. Two patients in Group A had a small split in
the proximal femoral shaft, which was treated with a cer-
clage wire. Three patients in Group S had a crack in the
greater trochanter (two at prosthesis removal and spacer
insertion and another one at reimplantation), which
required no treatment. Seven patients had complications
during the perioperative period.
One patient in Group S had postoperative bleeding that
required the draining of a hematoma, the stapling of minor
vessels and the use of hemostatic agents. One in Group A
and two in Group S had a deep vein thrombosis diagnosed
on routine postoperative Doppler ultrasound; in one patient
in Group S, it was above the knee and resulted in a pul-
monary embolus. One patient in Group S had transient
peroneal nerve palsy and one patient in each group had hip
dislocation, which was treated surgically in the patient in
Group S by changing the modular neck of the prosthesis.
The overall complication rate, including intraoperative
complications, postoperative deep venous thrombosis and/or
pulmonary embolism, postoperative hemorrhage, disloca-
tion and nerve palsy, was greater in Group S than in Group
A: 4 of 40 (10%) patients in Group A had complications,
and 9 of 40 (20.8%) in Group S. No femoral components or
acetabular cups were radiographically loosened at the latest
follow-up. However, three patients in Group A and two in
Group S had osteolysis in femoral Gruen Zone 1, and two
more had osteolysis in Zone 7. One more femoral com-
ponent in Group S required revision at 2 years for aseptic
subsidence.
Mean overall hospital-related costs of two-stage revision
of septic THAs (60,394 ± 15,886 euros) were 2.2 times
greater than those associated with aseptic revision
(27,194 ± 5,122 euros) (Table 4). Only pharmaceutical
costs were similar between the two groups.
Discussion
Although patient satisfaction and quality of life improve-
ments have been shown by different authors to be better
after primary than after revision surgery in the hip [11, 12,
25, 29], little is known from prospective comparative
studies about patient function and quality of life and the
reasons for THA revision. On the other hand, conﬂicting
results have been reported upon comparing septic and
aseptic TKA revision, with some papers showing inferior
[4, 33] and others superior [24, 26] knee scores and/or
patient satisfaction and quality of life for two-stage septic
versus aseptic TKA revision surgery. In this study, we
compared the medium-term hip functions, QOLs, and
complication rates of two cohorts of patients operated on
for aseptic or septic THA revision.
Our study has several limitations. First, the preoperative
comorbidities differed among the two groups, with more B
hosts in the septic patients. This is not an unexpected
ﬁnding due to the relative odds ratio for different comor-
bidities with respect to the risk of postoperative infection,
and it represents a bias that is difﬁcult to completely
overcome when comparing populations of patients with
and without septic complications. Considering the limited
number of patients, it was not possible to assess if there
were different postoperative morbidities or direct medical
costs for the A and B hosts within each group. Second, the
follow-up is relatively short, and more prolonged obser-
vation is needed to provide information on long-term
implant survivorship and occurrence of infection in the two
groups. Third, our analysis of direct medical costs did not
consider readmissions, outpatient visits and charges, or
nonmedical or indirect costs to the patient and to society
associated with lost productivity. Considering the pro-
longed period of convalescence usually associated with
septic THA revision, the inclusion of these other costs
would probably strengthen the conclusion that septic
revision is associated with greater resource use than revi-
sion for aseptic loosening. Caution should also be applied
Table 3 WOMAC scores
Preoperative data Group A (N = 40) Group S (N = 40) P value
Function 41.7 ± 22.3 56.7 ± 17.8 0.001
Pain 43.9 ± 17.9 52.6 ± 22.7 0.06
Stiffness 41.2 ± 22.9 44.9 ± 23.8 0.48
Postoperative data Group A (N = 38) Group S (N = 39) P
Function 66.2 ± 22.3 76.6 ± 21.3 0.04
Pain 75.8 ± 24.0 77.4 ± 22.8 0.76
Stiffness 70.1 ± 22.5 71.4 ± 24.1 0.80
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123when generalizing those data, since treatment regimes and
resource valorization may vary among countries and
hospitals.
Two-stage reimplantation with a cement-impregnated
spacer remains the gold standard and the most commonly
performed intervention for patients with infected hip
arthroplasty. Our data show that hip function, as deter-
mined through the Harris hip score, was similar in the two
cohorts of patients studied, notwithstanding the reason for
revision. The WOMAC score is a reliable and sensitive tool
for measuring QOL and outcome after THA [21, 22]. We
found better functional WOMAC scores both pre- and
postoperatively in Group S compared with Group A. One
possible explanation for this is the occurrence of more
patients with septic complications that came to our atten-
tion with otherwise well-ﬁxed and relatively pain-free
prostheses. In line with this interpretation is the ﬁnding of
an average lower self-reported preoperative pain score in
patients in Group S than in Group A. In a paper comparing
aseptic cases of knee prosthetic revision with two-stage
revision of septic knees using an articulated spacer, Meek
et al. [24] reported that two-stage exchange provided
comparable patient satisfaction and functional results
(WOMAC, Oxford-12, SF-12, patient satisfaction data and
range of motion). The authors noted ‘‘statistically better
postoperative function scores for the septic group,’’ similar
to those observed in our hip study, and suggested that
‘‘perhaps it is not that the septic revisions are doing better
than expected, but that the aseptic revisions may often do
worse than is presently assumed.’’ Similar ﬁndings have
been more recently reported by Patil and coworkers [26].
Our study also shows similar infection recurrence rates in
the two groups at medium-term follow-up, whereas the
overall complication rate after septic surgery is approxi-
mately twice that after aseptic revision. We interpret this
latterﬁndingastheconsequenceofsubmittingthepatientsto
two procedures instead of one without any substantial
additional risk of complication resulting from infection
itself.Inthisregard,ourdataareslightlydifferentfromthose
reportedbyBozicandcoworkers[6],whoshoweda2.7-fold
increase in the complication rate in patients operated on for
two-stage hip revision compared with one-stage aseptic
cases,suggestinganadditionalinfectionriskfromtwo-stage
procedures compared with one-stage for aseptic cases.
Direct medical costs associated with revision THA
because of aseptic loosening were reportedly up to 4.8-fold
higher than the direct medical costs associated with pri-
mary THA [6]. Sculco [32] evaluated the economic impact
of infection after total joint arthroplasty. Noting the dis-
proportionate burden of care associated with septic hip
revision surgery, he recommended that a method for case
sharing should be established by medical centers that are
best equipped to care for these patients, and that reim-
bursement to both hospitals and physicians should more
realistically adapted to the magnitude of resources con-
sumed by these patients. Direct medical costs associated
with revision THA due to infection were 2.2 times higher
than those for aseptic loosening in our study. This ﬁnding is
in accordance with those described previously by other
authors. Hebert et al. [16] reported that the surgical treat-
ment of patients with an infection after TKA was approx-
imately twice as expensive as that required for revision
TKA because of aseptic loosening, whereas Bozic [6]
reported that total direct medical costs associated with
revision THA due to infection were 2.8 times higher than
the direct medical costs associated with revision THA due
to aseptic loosening. In this regard it should be noted that
calculating the costs of two-stage versus one-stage aseptic
revision is not just a matter of ‘‘two procedures versus
one.’’ While septic cases may require more extensive and
lengthy surgery and costlier medical treatment, the ﬁrst-
stage procedure is less expensive than a reimplantation
procedure (the cost of the spacer, even if it is a preformed,
off-the-shelf device, is much less than the cost of a revision
prosthesis; the surgical time needed to implant a spacer is
often less that that required to implant the revision femoral
and acetabular prosthesis, etc.).
In conclusion, our data suggest that at medium-term
follow-up, two-stage revision of septic hip arthroplasty
with the use of a preformed antibiotic-loaded cement
spacer and a cementless modular revision prosthesis may
provide functional results, as the Harris hip score and QOL
improvements were comparable to those obtained after
revision for aseptic loosening. The higher complication rate
Table 4 Mean direct hospital
costs (in euros) per
patient ± SD
Hospital resource Group A Group S Group S/Group A P value
Operating room equipment and implants 10,620 ± 5938 18,367 ± 9029 1.7 0.0001
Operative time and staff 4529 ± 1522 9458 ± 7533 2.1 0.0001
Hospital stay 6901 ± 4796 21,442 ± 7522 3.1 0.0001
Material services 2122 ± 1285 5284 ± 1782 2.5 0.0001
Blood products 1668 ± 1980 2421 ± 1208 1.4 0.04
Pharmacy 1354 ± 6076 3422 ± 6584 2.5 0.14
Total 27,194 ± 5122 60,394 ± 15886 2.2 0.0001
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123and the additional resource use required to provide care for
patients with an infection after total joint arthroplasty
should prompt healthcare systems to provide adequate
reimbursements and/or to develop specialized centers with
dedicated, appropriate funding to better manage these
challenging cases.
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